|
業務類別
|
Biotechnology |
|
業務概覽
|
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. |
| 公司地址
| 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355 |
| 電話號碼
| +1 484 875-3192 |
| 傳真號碼
| +1 610 727-4001 |
| 公司網頁
| https://www.annovisbio.com |
| 員工數量
| 8 |
| Dr. Maria Maccecchini, PhD |
Acting Chief Financial Officer, Director, President and Chief Executive Officer |
美元 734.80K |
25/03/2026 |
| Ms. Sarah MacCallum |
Vice President, Clinical Operations |
-- |
14/04/2026 |
| Mr. Hui Liu |
Director of Biostatistics |
-- |
14/04/2026 |
| Mr. Alexander Morin, PhD |
Director, Strategic Communications |
-- |
14/04/2026 |
|
|
| Dr. Maria Maccecchini, PhD |
Acting Chief Financial Officer, Director, President and Chief Executive Officer |
25/03/2026 |
| Mr. Michael M.B. Hoffman |
Chairman of the Board |
13/03/2026 |
| Dr. Claudine E. Bruck, PhD |
Independent Director |
13/03/2026 |
| Mr. Mark White |
Director |
13/03/2026 |
| Mr. Reid S. McCarthy |
Independent Director |
13/03/2026 |
|
|
|
|
